Neoplasms of the central nervous system in Norway. V. Meningioma and cancer of other sites. An analysis of the occurrence of multiple primary neoplasms in meningioma patients in Norway from 1955 through 1986.
46
Citation
0
Reference
10
Related Paper
Citation Trend
Abstract:
The association between meningioma and a primary malignant neoplasm at another site was studied. The data from the population-based Norwegian Cancer Registry were analysed according to whether the meningioma occurred before or after the malignant neoplasm. Male patients with meningioma showed a raised risk for developing a subsequent renal cancer. A significant association was found between meningioma and subsequent breast cancer in females 50-64 years old at time of meningioma diagnosis and between breast cancer and subsequent occurrence of meningioma. Breast cancer patients with symptoms of an intracranial neoplasm may therefore have a potentially curable meningioma and female meningioma patients over 50 years should be considered for breast cancer screening programmes.Keywords:
Norwegian
Neoplasm
Cite
Abstract Background: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer. Our group's recent study revealed that the 5-year breast cancer specific survival for IBC is 49%, an improved rate compared to historical studies (∼ 30%). This could be attributed to evolution in modern modalities of treatment including utility of transtuzumab. Given marginally improved survival, these women are also at risk for second breast cancers. Here we investigate the risk of second breast cancer in IBC compared to the general population.Methods: We identified 75,039 IBC, LABC and non-T4 female breast cancer cases in the California Cancer Registry during the period of 1999-2005. We excluded synchronous tumors (cancer diagnosed <6 months from first breast cancer diagnosis). Standardized incidence ratio (SIR) with 95% CI is used to calculate the risk of second breast cancer by comparison to underlying general population.Results: A total of 1488 second breast cancer patients were identified, including 60 with a first diagnosis of IBC, 26 with a first diagnosis of LABC, and 1402 with a first diagnosis of non T-4 breast cancer. The risk of second breast cancer in IBC compared to the underlying population at risk was observed to be highest in IBC [SIR= 4.12 (3.14-5.30)] followed by LABC [SIR= 1.95 (1.28-2.86)], and non-T4 [SIR= 1.16 (1.10-1.23)] cases. Patients with IBC were more likely to be [HR-/HER2+] (43.8%) compared to LABC (33.3%) and non-T4 (8.7%) [p=<0.0001]. IBC and LABC were also increasingly associated with contralateral breast cancer (96%).Table-1: Risk of second breast cancer compared to general population by classification of first breast cancer Cohort sizeObserved 2nd breast cancerExpected 2nd breast cancerSIR (95%CI)IBC14746014.574.12 (3.14-5.30)LABC11032613.321.95 (1.28-2.86)Non-T472,46214021205.851.16 (1.10-1.23) Table-2: Hormone Receptor/Her2-neu status, subtype, laterality of second breast cancer by classification of first breast cancer £Receptor status of the first tumor*IBCLABCNon-T4TotalHR+/Her2+147(17%)123(20%)6405(15.5%)6675(15.7%)HR-/Her2+217(25%)98(16%)2713(6.6%)3028(7.1%)HR+/Her2-318(36.5%)268(43.8%)26,680(65%)27,266(64%)HR-/Her2-187(21.5%)124(20.2%)5303(12.9%)5614(13.2%)Receptor status of the second tumor** HR+/Her2+2 (6.2%)4 (26.7%)97 (12.6%)103 (12.6%)HR-/Her2+14 (43.8%)5 (33.3%)67 (8.7%)86 (10.5%)HR+/Her2-11 (34.4%)6 (40%)468 (60.6%)485 (59.2%)HR-/Her2-5 (15.6%)0 (0%)140 (18.1%)145 (17.7%)Subtypes of the 2nd primary breast tumor*** OtherIBC11(18.3%)2(5%)13(21.7%)33(55%)LABC5(19%)1(4%)11(42.4%)9(34.6%)Non-T425(1.8%)8(0.5%)482(34.4%)887(63.2%)Contralateral Breast cancer58(96.6%)25(96.1%)1165(83%)1484£ p value <0.0001 for all comparisons, *43% of data missing;** 49% of data missing;*** 8% of data missing.Conclusions: HR-/HER2+ biologic subtype of IBC was increasingly associated with development of second breast cancers and majority of them (96%) involved the contralateral breast with possible implications for IBC treatment. Among the investigated breast cancer subtypes IBC was associated with the highest risk of second breast cancers compared to the underlying population reinforcing IBC as an unique biologic entity. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2056.
Inflammatory breast cancer
Cite
Citations (0)
Breast cancer is the most common cancer in most part of the world and it is the most common cancer among Malaysian women. In order to estimate the overall survival and prognosis, it was decided that a National Cancer Patient Registry-Breast cancer be set up. It would be a tracking system form for breast cancer patients in Malaysia to help treatment outcomes. There would be useful for evaluating clinical management.
Cite
Citations (4)
MicroRNA (miRNA), which are stably present in serum, have been reported to be potentially useful for detecting cancer. In the present study, we examined the expression profiles of serum miRNA in several large cohorts to identify novel miRNA that can be used to detect early stage breast cancer. We comprehensively evaluated the serum miRNA expression profiles using highly sensitive microarray analysis. A total of 1280 serum samples of breast cancer patients stored in the National Cancer Center Biobank were used. In addition, 2836 serum samples were obtained from non‐cancer controls, 451 from patients with other types of cancers, and 63 from patients with non‐breast benign diseases. The samples were divided into a training cohort including non‐cancer controls, other cancers and breast cancer, and a test cohort including non‐cancer controls and breast cancer. The training cohort was used to identify a combination of miRNA that could detect breast cancer, and the test cohort was used to validate that combination. miRNA expressions were compared between patients with breast cancer and non‐breast cancer, and a combination of five miRNA (miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p) was found to be able to detect breast cancer. This combination had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% for breast cancer in the test cohort. In addition, this combination could detect early stage breast cancer (sensitivity of 98.0% for Tis).
Cite
Citations (311)
In 2009, the first National Population-based Cancer Registry (NCR) was established in Sudan. We report in this study, the first data from the NCR for Khartoum State for the period 2009-2010. The NCR staff used passive and active approaches to collect data on cancer diagnosed by all means in Khartoum State. Rates were age standardized to the 2010 Sudan Standard Population and 1966 and 2000 World Standard Population and expressed per 100,000 populations. During 2009-2010, 6771 new cancer cases were registered. Of those, 3646 (53.8%) cases were in women and 3125 (46.2%) were in men. The most commonly diagnosed cancer among women was breast followed by leukemia, cervix, and ovary, and among men it was prostate cancer followed by leukemia, lymphoma, oral, colorectal, and liver. In children less than 15 years of age, leukemia was the most common cancer followed lymphoma, and cancer of the eye, bone, kidney, and the brain. The overall age-standardized rate (ASR) per 100,000 population was higher in women (124.3) than in men (90.8) using 2010 Sudan Standard Population. Similarly, it was higher in women (188.6 and 206.3 per 100,000 population) than in men (145.4 and 160.0 per 100,000 population) using 1966 and 2000 World Standard Population, respectively. The data from NCR indicated that prostate and breast as the most commonly diagnosed cancer sites in men and women in Khartoum, while cancer of the cervix trailed behind portraying a cancer picture similar to that of the developed world. Despite the study limitations, the NCR data gave a fair representation of cancer profile of Khartoum State and underscored the need for high-quality cancer registries in Sudan.
Cite
Citations (113)
An association between breast cancer and intracranial meningioma has been described in women. We sought to determine whether this connection exists in men as well, hypothesizing that causes unrelated to sex may be responsible.We queried state cancer registries that recorded data on breast cancer and meningioma. International Classification of Diseases for Oncology codes for breast cancer and meningioma were used. The incidence rate of the second primary tumor was compared between identified meningioma and breast cancer cohorts and the general population for each sex.Five state registries collected data on men and women from 1995 to 2003. The incidence of meningioma was 2.6 and 0.96 (cases per 100,000) for women and men, respectively, during this period. The incidence of breast cancer was 61 and 0.69 (cases per 100,000) for women and men, respectively, during this period. One man and 439 women were diagnosed with both diseases. The standardized incidence ratio was used to determine the magnitude of association between breast cancer and meningioma. During the study period, the standardized incidence ratio indicated a stronger than expected association between breast cancer and meningioma in women, regardless of which disease was diagnosed first. In every year except one, the standardized incidence ratio indicated no association between breast cancer and meningioma in men, regardless of which disease was diagnosed first.Our results support a strong association between meningioma and breast cancer in women. Conversely, we were unable to show as strong an association in men. This suggests that the connection between these diseases may be dependent on sex.
Cite
Citations (40)
Abstract Abstract #3099 Background: Molecular marker expression analyses have led to the identification of unique breast cancer subtypes that have clinical and prognostic importance. Using data from a large population-based breast cancer cohort, we report results examining combined HER2/neu and estrogen receptor (ER) subtype distribution in relation to patient and tumor characteristics as well as breast cancer specific survival.
 Methods: We conducted a retrospective cohort study of 1,645 female members of a large managed care organization newly diagnosed with invasive breast cancer from 1988 to 1995. We collected patient, tumor, treatment, and outcome information from medical records and electronic cancer registry files. We used immunohistochemistry techniques to evaluate gene expression of specific molecular markers including HER2/neu and estrogen receptor (ER). We examined prevalence of markers as well as odds ratios (OR) and 95% confidence intervals (CI) comparing outcomes by marker expression.
 Results: Women with HER2+/ER- tumors were more likely to have been diagnosed at a younger age (less than age 60) than women with luminal A subtype (HER2-, ER+ and/or PR+) tumors (65.5% versus 47.8%, P<0.0001). A higher proportion of women with HER2+/ER- tumors were other than white race compared with women with luminal A subtype (21.8% versus 11.6%, P=0.007). Women with luminal B (HER2+, ER+ and/or PR+) or basal-like (HER2-, ER-, PR) subtype tumors were similarly more likely to be older at diagnosis and from minority backgrounds than women with luminal A subtype. Family history of breast cancer was not clearly associated with HER2/ER subtype. Women with luminal A tumors were more likely to be diagnosed with stage 1 disease than women with other tumor subtypes (luminal A: 56.3%; luminal B: 38.9%; basal-like: 38.1%; HER2+/ER-: 25.5%; P<0.0001). Residual tumor in surgical margins was not associated with HER2/ER subtype. Compared with women with luminal A tumors, women with HER2+/ER- tumors were much more likely to die of their cancers overall (OR=6.5, CI=3.5-11.9), and by stage (stage 1: OR=11.5, CI=2.6-50.3; stage 2: OR=3.8, CI=1.6-9.2; stage 3/4: OR=9.0, CI=1.1-77.2). Odds of breast cancer death, overall and by stage, was also increased for women with luminal B and basal-like subtype tumors compared with women having luminal A subtype.
 Conclusions: HER2/ER subtype was clearly associated with patient as well as tumor characteristics in this large cohort of breast cancer patients. Specific tumor subtypes (HER2+/ER-, luminal B, and basal-like) were also associated with increased likelihood of dying of breast cancer. Further work is warranted to define treatment strategies by molecular subtypes. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3099.
Cite
Citations (0)
Cancer is one of the most important causes of death in the world and has an increasing trend globally. We aimed at investigating the five leading cancers in Iranian women based on a 10-year history of cancer registry reports and illustrating the trends in all cancer sites and breast cancer as the top leading one from 2003 to 2015.Data were obtained from national cancer registry study. Age-Specific Incidence Rate (ASR) data were obtained from Iran's annual national cancer registry reports between 2003 to 2010 and 2014 to 2015. Using Joinpoint regression, we analyzed incidence trends over time for all cancer sites and the top leading cancer from 2003 to 2015.Breast cancer was ranked first in Iranian women. Its ASR raised from 15.96 in 2003 to 32.63 in 2015. Results of trend analysis based on Annual Percent Change (APC) index showed 5.6 (95%CI: 2.9 to 8.3) and 4.6 (95%CI: 2.0 to 7.2) annual increase in the incidence of all cancer sites and breast cancer from 2003 to 2015, respectively.This study indicates significant increasing trends in all cancer sites and breast cancer incidence in Iran. Despite the national coverage of cancer registry over the past decade, more considerations should be taken into account, especially in Breast cancer.
Cancer Incidence
Cite
Citations (3)
Abstract Background: Prior studies have shown significant improvements in earlier breast cancer stage at diagnosis following Medicaid expansion. However, the mechanisms behind this finding have not been explored. The timing of Medicaid enrollment among cancer patients has been shown to be associated with cancer stage at diagnosis, with significantly higher percentages of women with late-stage breast cancer enrolling in Medicaid shortly before or after cancer diagnosis (hereafter referred to as the Peri-dx group), compared to those continuously enrolled in Medicaid at least 4 months prior to cancer diagnosis (Pre-dx group). Hence, we conducted a causal mediation study based on a logistic regression model to determine whether the observed improvements in breast cancer stage at diagnosis from Pre- to Post-expansion can be attributed to a decreasing percentage of women in the Peri-dx group, and a corresponding increase in the Pre-dx group. Methods: We used the linked Ohio Cancer Incidence Surveillance System and Medicaid data, and identified women in Ohio age younger than 66 years, diagnosed with incident invasive breast cancer during the period May 2011-December 2017, and enrolled in Medicaid at the time of cancer diagnosis (n=5,880, excluding those with unstaged/unknown-stage cancer). We defined the years 2011-2013 and 2014-2017 as the Pre- and Post-expansion periods, and Month 0 as the month of cancer diagnosis. We identified women enrolled in Medicaid in the -3 to +3-month window in the Peri-dx group, and those continuously enrolled in Medicaid at least 4 months prior to cancer diagnosis in the Pre-dx group. We conducted a causal mediation analysis to estimate the direct, indirect, and total effect of Medicaid expansion on being diagnosed with local-stage disease versus late- (regional- and distant-) stage disease, with the mediator variable being a patient in the Pre-dx group (versus in the Peri-dx group), adjusting for patient- and area-level covariates. Results: The median age of our study population was 53 years; 75.0% were non-Hispanic White. The percent of breast cancer patients diagnosed with late-stage disease was 43.5% and 53.4% in the Pre- and Peri-dx groups, respectively. We observed a clear shift in the distribution of breast cancer patients from the Peri- to the Pre-dx group over time, with an increase in the percentage of women in the Pre-dx group (from 55.2% to 74.2% from the Pre- to Post-Expansion period), and a corresponding decrease in the Peri-dx group (from 44.8% to 25.8%). Findings from our causal mediation analysis, based on a risk difference scale, showed that while the direct effect of Medicaid expansion on being diagnosed with local-stage disease was not significant (coefficient: 0.037, (p=0.297)), both the indirect and total effects were highly significant (0.049 (p < 0.001), and 0.086 (p=0.015)). Conclusion: Our results indicate that the improvements in breast cancer stage at diagnosis from Pre- to Post-Expansion can be attributed to a decrease in the Peri-dx group, and a corresponding increase in the Pre-dx group, which improves access to screening, increases the likelihood of breast cancer patients being engaged with Medicaid providers, and reduces delays in enrollment logistics prior to treatment initiation. Citation Format: Siran M. Koroukian, Weichuan Dong, Jeffrey Albert, Uriel Kim, Johnie Rose, Cynthia Owusu, Kristine Zanotti, Gregory Cooper, Jennifer Tsui. Impact of medicaid expansion on breast cancer stage at diagnosis: Exploring the mechanisms at play [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-12-30.
Cite
Citations (0)
The association between meningioma and a primary malignant neoplasm at another site was studied. The data from the population-based Norwegian Cancer Registry were analysed according to whether the meningioma occurred before or after the malignant neoplasm. Male patients with meningioma showed a raised risk for developing a subsequent renal cancer. A significant association was found between meningioma and subsequent breast cancer in females 50-64 years old at time of meningioma diagnosis and between breast cancer and subsequent occurrence of meningioma. Breast cancer patients with symptoms of an intracranial neoplasm may therefore have a potentially curable meningioma and female meningioma patients over 50 years should be considered for breast cancer screening programmes.
Norwegian
Neoplasm
Cite
Citations (46)
A retrospective registry-based cohort study was conducted to examine the risk of second primary cancer following the occurrence of breast cancer in males.Data obtained from the California Cancer Registry in the period 1988 to 2003 included 1,926 men aged 85 years and younger diagnosed with a first primary breast cancer. Person-year analysis was applied to determine the risk of second primary cancers after the occurrence of a first primary breast cancer. The effects of age, race, and time since the first breast cancer diagnosis were assessed.Of the 1,926 male breast cancer cases, 221 (11.5%) developed a second primary cancer. Men with first incidence of breast cancer have a significantly higher risk of second cancer (standardized incidence ratio (SIR) = 1.16, 95% confidence interval (CI) = 1.01-1.32). The risk of a second site-specific cancer is elevated for breast cancer (SIR = 52.12, 95% CI = 31.83-80.49), cutaneous melanoma (SIR = 2.98, 95% CI = 1.63-5.00) and stomach cancer (SIR = 2.11, 95% CI = 1.01-3.88). There is a general tendency towards higher risks of second malignancies among younger men compared to older men and the risk increased with the passage of time.Male breast cancer patients should be monitored carefully for the occurrence of second primary cancers, especially a second primary breast cancer.
Surgical oncology
Male Breast Cancer
Cite
Citations (57)